ESTEVE's Expansion in the US and EU Fuels Global Pharmaceutical Growth

BARCELONA, Spain — ESTEVE recently unveiled its financial results for 2025, showcasing a year that exemplified robust strategic execution alongside significant growth. Throughout the year, the company experienced a double-digit increase in both net revenues and EBITDA, reflecting its successful strategy to expand its global footprint in the pharmaceutical industry.

In detailing its performance, ESTEVE reported a 14% rise in net revenues, bringing the total to 828 million euros. The company’s EBITDA also surged by 19%, verifying the strength of ESTEVE's dual business model, which encompasses both its Pharma and CDMO (Contract Development and Manufacturing Organization) operations. This growth trajectory, marked by the acquisition and integration of new, specialized pharmaceutical products, aligns with ESTEVE’s long-term vision of becoming a leading international pharmaceutical company.

Strategic Ventures in Pharma and CDMO

In the past 18 months, ESTEVE successfully integrated eight new products into its portfolio, predominantly focusing on specialized medications catering to patient populations with unmet medical needs, especially within oncology and endocrinology sectors. A key milestone was the acquisition of TerSera’s infusion therapy unit in March 2026, further expanding ESTEVE's specialized offerings.

Simultaneously, the company bolstered its CDMO operations with the acquisition of Regis Technologies in the United States. This venture not only enhances ESTEVE’s capacity for early-stage development but also solidifies its presence in the US pharmaceutical market, the largest in the world. ESTEVE’s capability to offer comprehensive support across the entire value chain—from initial development to commercial manufacturing—positions it competitively within the CDMO sector.

Commitment to ESG and Sustainability

A cornerstone of ESTEVE’s growth strategy is its commitment to environmental, social, and governance (ESG) standards. In 2025, the company received B Corp certification, underscoring its dedication to high social and environmental performance metrics. Esteve actively integrates sustainability into its operations, implementing initiatives aimed at achieving net-zero emissions while improving waste management and utilizing renewable energy.

Furthermore, ESTEVE’s efforts have positively impacted communities globally through partnerships with patient organizations and health institutions, showcasing a commitment not only to business growth but also to enhancing societal well-being. With a workforce of over 2,200 employees spanning 35 nationalities, ESTEVE recorded an impressive 87% engagement rate among staff, indicative of a robust company culture focused on transparency and responsibility.

Future Growth Prospects

Looking ahead, ESTEVE is set on a trajectory targeting 1 billion euros in revenue by 2027, propelled by both organic growth and strategic acquisitions within its Pharma and CDMO divisions. The company plans to maintain its high investment levels in product development and technology, with a reported commitment of 49 million euros allocated in 2025, signifying a proactive approach to innovation and expansion.

Overall, ESTEVE's resilience and commitment to its dual business model are key drivers of its ongoing success and transformation into a noteworthy player on the global pharmaceutical stage, illustrating how strategic expansion in key markets can bolster both financial performance and social responsibility.